Author: James Love

Knowledge Ecology International (KEI) comments
U.S. House of Representatives, Committee on Ways and Means, Subcommittee on Trade, March 13, 2013 Hearing on U.S.-India Trade Relations

Name: James Love
Organization: Knowledge Ecology International
Address: 1621 Connecticut Avenue NW, Suite 500, Washington, DC 20009
Phone Number: 1.202.332.2670
Contact E-mail Address: James.Love@KEIonline.Org
Title of Hearing: U.S.-India Trade Relations

Introduction

Continue Reading →

On March 13, 2013, the U.S. House of Representative held a hearing on U.S.-India Trade Relations. Among the several topics under discussion were “the issuance of compulsory licenses, patent revocations, and other policies on pharmaceuticals” in India.

Continue Reading →

As others have reported, the India Intellectual Property Appeals Board (IPAB) has upheld the compulsory license on the Bayer patents on the cancer drug sorafenib, sold under the trademark of Nexavar by Bayer.

Continue Reading →

KEI comment on the Medicines Patent Pool license and MoU with ViiV Healthcare
28 February 2013

FYI: James Love (james.love@keionline.org, +1.202.361.3040), Krista Cox (krista.cox@keionline.org, +1.202.332.2670) or Thiru Balasubramaniam (thiru@keionline.org).

The 27 February 2013 agreements between the Medicines Patent Pool (MPP) and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shionogi will expand access to affordable pediatric formulas for HIV/AIDS.

Continue Reading →

On January 8, 2013, the US Department of Justice (DOJ) and the U.S. Patent and Trademark Office (PTO) issued a joint statement on “remedies for standards-essential patents subject to voluntary F/RAND commitments. (Copy of statement here). Continue Reading →

WIPO is spending five days in a special session to work on the text for a treaty on copyright exceptions for persons who are blind or have other disabilities.

KEI has obtained a copy of the latest version as of Friday morning, which is attached below.

The first four days have been consumed with highly technical but important debates of the international rules for copyright exceptions. The US and the EU are demanding that all sorts of language be put into the treaty referring to a three step test to restrict the use of exceptions.

Continue Reading →

These are KEI’s February 17, 2013 comments on the the Bayer appeal of the compulsory license on Nexavar patents.

Comments on the the Bayer appeal of the compulsory license on Nexavar patents.

February 17, 2013

The dispute is Bayer Corporation v Natco Pharma Limited, and is being heardbefore the Intellectual Property Appellate Board At Chennai (O.R.A. no. 35/PT/2012).

Continue Reading →

For the past year, a treaty on copyright exceptions for persons who are blind or have other disabilities has been hung up on demands by the European Union to insert provocative language on the so called “three step test” in copyright into the treaty. The Trans Pacific Partnership Agreement is in the middle of a similar dispute, with the US pushing language that would place the three step test on top of all copyright limitations and exceptions, including those set out a particular cases in the Berne Convention. Continue Reading →

The WIPO Special Session negotiating the text of a new treaty on copyright exceptions for persons with disabilities is meeting from February 18 to 22. Yesterday all of the negotiations were behind closed doors, but this morning WIPO made public a copy of the revised negotiating text (available here: https://www.keionline.org/node/1651).

Continue Reading →